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Abstract
Introduction: Methotrexate (MTX) exerts at least part of its anti-inflammatory effects through adenosine receptors
(ADOR). The aims of this study were to determine the expression of all four adenosine receptor genes (ADORA1,
ADORA2A, ADORA2B, ADORA3 and ADORA3variant) in rheumatoid synovial tissue and any influence of MTX exposure
on this expression. Furthermore, we investigated whether polymorphisms within ADORA3 were associated with
response and/or adverse effects associated with MTX.
Methods: Adenosine receptor gene expression was undertaken using PCR in 20 rheumatoid arthritis (RA) synovial
samples. A separate cohort of 225 RA patients receiving MTX was genotyped for SNPs in the ADORA3 receptor
gene. Double immunofluorescence was used to identify cells expressing ADOR protein.
Results: All ADOR genes were expressed in all synovial samples. ADORA3 and A3variant were the dominant subtypes
expressed irrespective of MTX therapy. Expression of ADORA2A and ADORA2B was increased in patients receiving
MTX compared to those not receiving MTX. There was no association between the ADORA3 rs1544224 SNP and
high and low disease activity or MTX-associated adverse effects. ADORA2B protein expression was most obvious in
vascular endothelial cells whereas ADORA3 protein was more abundant and expressed by synovial fibroblasts.
Conclusions: We have shown that adenosine receptors are expressed in RA synovium. There is differential
expression of receptors such that ADORA3 is expressed at significantly higher levels. This evidence demonstrates
the potential for MTX to exert its anti-inflammatory effects at the primary site of pathology within the joints of
patients with RA.
Introduction
Methotrexate (MTX) remains the first line drug for the
treatment of rheumatoid arthritis (RA). The exact
mechanism of action of MTX is complex. Following
administration and absorption, serum MTX concentra-
tions fall rapidly [1] as MTX is transported into a vari-
ety of cells including red blood cells (RBC) and
synoviocytes. Intra-cellularly, glutamate moieties are
added by folylpolyglutamate synthetase (FPGS) such that
MTX is retained within cells as MTX polyglutamates
(MTXGlun).
MTX polyglutamates inhibit a number of important
intracellular enzymes in the folate pathway including
dihydrofolate reductase and thymidylate synthase. Inhi-
bition of 5-aminoimidazole-4-carboxamide
ribonucleotide (AICAR) transformylase (ATIC) results
in accumulation of AICAR and increased adenosine
release into the circulation. Extracellular adenosine
increases cAMP which inhibits production of pro-
inflammatory cytokines including TNF-a, IFN-g and IL-
1b, which are important in the inflammatory process in
RA.
Adenosine acts via four G-coupled adenosine recep-
tors (ADOR); ADORA1, ADORA2A, ADORA2B and
ADORA3. Activation of the ADORA1 and ADORA2B
results in pro-inflammatory effects which include an
increase in pro-inflammatory cytokine release from neu-
trophils and monocytes. In contrast, activation of the
ADORA2A and ADORA3 results in anti-inflammatory
effects with a reduction in IL-1b, TNF-a, IL-6, and
decreased neutrophil superoxide production. In part,
these opposing effects reflect patterns of ADOR subtype
expression associated with distinct cell lineages and
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differentiation states, as well as linkage to divergent G
protein mediated signaling pathways [2].
ADORA3 is highly expressed in rat synovium, periph-
eral blood mononuclear cells (PBMC) and lymphocytes
[3]. In murine studies, MTX has been shown to exert its
anti-inflammatory effects via ADORA2A and ADORA3
[4]. In MTX-treated RA patients the ADORA3 has been
reported to be expressed at higher levels on PBMC
compared to healthy controls [5]. Furthermore, expres-
sion of ADORA2A, ADORA2B and ADORA3 appear to
be regulated by inflammatory cytokines such as TNF-a
[6-8].
In an experimental model using cultured human
monocytes MTX, an ADORA1 agonist and an ADORA2
antagonist were shown to enhance the formation of
multi-nucleated giant cells from monocytes. The authors
suggest that within the joint MTX may increase adeno-
sine concentrations to the extent that ADORA2 are
bound with resulting anti-inflammatory effects [9].
Whether the adenosine receptors are expressed in
human joint synovial tissue, the primary lesion in RA is
unknown. Furthermore, MTX through its anti-inflam-
matory effects may alter the expression of adenosine
receptors within the synovium. We hypothesized that
synovial tissue will express adenosine receptors and
there will be a relationship between MTX exposure and
adenosine receptor expression within the synovium.
Furthermore, we hypothesized that polymorphisms
within ADORA3 may be associated with response and/
or adverse effects associated with MTX.
Methods
Ethical approval was obtained from the Multi-Regional
Ethics Committee and the Upper South B Regional
Ethics Committee, New Zealand. All patients gave writ-
ten informed consent obtained according to the
Declaration of Helsinki. Two cohorts of patients with
RA as defined by the 1987 American Rheumatism Asso-
ciation criteria [10] were recruited. The first cohort (n =
20) were used for synovial tissue gene expression studies
while the second cohort (n = 225) were used for the
ADORA3 genotyping. There was no overlap of the two
patient cohorts.
Synovial tissue samples - PCR and QT-PCR
Synovial tissue was obtained from the first cohort of
twenty RA patients undergoing joint surgery. Total RNA
was extracted from the synovial tissue using Qiagen
RNeasy mini kits. Either 0.5 or 1 μg of RNA was reverse
transcribed at 42°C for 50 minutes using Superscript III
(Life Technologies, Carlsbad, CA USA) and Oligo (dT)12
- 18 primers. Expression of ADORA1, A2A, A2B, A3 and
A3variant were examined. Quantitative real-time PCR was
undertaken using TaqMan gene expression assays
(Applied Biosystems, Foster City, California, USA) for
ADORA1 (Assay ID: Hs00379752_m1), ADORA2A
(Hs00169123_m1) and ADORA2B (Hs00386497_m1).
We also measured three alternative transcripts produced
from the ADORA3 gene - the ADORA3 assay
(Hs00252933_m1) detects transcripts 1 and 3 while the
ADORA3variant assay (Hs00181232_m1) detects tran-
script variant 2 only. All values were normalized to
GAPDH (Hs999999905_m1).
DNA sequencing and genotyping of variants in ADORA3
A second cohort consisting of 234 RA patients receiving
MTX, were recruited as part of an unrelated cross-sec-
tional study [11]. DNA was extracted from 5 ml samples
of peripheral blood using phenol-chloroform [12-14].
The promoter, 5’ and 3’ UTRs, and the open reading
frame (ORF) of the ADORA3 gene were amplified in five
overlapping 680 bp to 750 bp fragments and subse-
quently sequenced in 15 patients with low disease activ-
ity (Disease Activity Score in 28 Joints (DAS28) < 3.2)
and 15 patients with high disease activity (DAS28 ≥ 3.2).
Briefly, each PCR was performed in a total volume of 20
μl containing 200 μM dNTPs, 2 mM MgCl2, 0.5 μM of
the relevant forward and reverse primers [see Additional
file 1, Table S1], 1 U of Platinum® Taq DNA polymer-
ase (Invitrogen, Carlsbad, CA, USA) and approximately
50 ng of DNA. Thermal cycling conditions comprised
an initial denaturation of 94°C for two minutes, followed
by 35 cycles of 94°C for 30 seconds, 60°C for 30 sec-
onds, 72°C for one minute, and a final extension of 72°C
for three minutes. Successful amplification was con-
firmed by analyzing 5 μl of each PCR by 1% agarose
electrophoresis. Complementary DNA was purified from
the remaining 15 μl of each PCR using PureLink™ PCR
Purification Kit (Invitrogen) according to the manufac-
turer’s instructions. Approximately 6 to 7 ng of purified
PCR product was sequenced in both directions using
BigDye® Terminator Version 3.1 chemistry on an ABI
3730xl DNA Analyzer.
Genotyping of the 5’UTR SNP rs1544224 within
ADORA3 was conducted using a two-tube allele-specific
PCR assay. Each reaction was performed in a total
volume of 10 μl containing 200 μM dNTPs, 2 mM
MgCl2, 0.5 μM of the control primers b2Mf and b2Mr,
0.5 μM of the common forward primer ADORA3U5f [see
Additional file 1, Table S1], 1 U of Platinum Taq DNA
polymerase (5 U/μl) (Invitrogen) and approximately 50
ng of DNA. Reaction 1 contained 0.5 μM of primer
rs1544224WT and reaction 2 contained 0.5 μM of pri-
mer rs1544224MU [see Additional file 1, Table S1].
Thermal cycling conditions comprised an initial dena-
turation of two minutes at 94°C, followed by 30 cycles
of 30 seconds at 94°C, 30 seconds at 65°C, 30 seconds
at 72°C, and a final extension of two minutes at 72°C.
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Sequence-validated positive controls for each genotype
(rs1544224 C/C, C/T, T/T) were included in all geno-
typing runs. Reactions were visualized using 3% agarose
gel electrophoresis. The primers b2Mf and b2Mr ampli-
fied a 567 bp region of the beta-2-microglobulin gene
(b2M) which served as an internal control for amplifica-
tion in samples where homozygosity for the SNP of
interest resulted in allele-specific PCR product in only
one reaction. The accuracy of the genotype was checked
by repeat analysis of 5% of the samples and by sequen-
cing PCR amplicons from a further 5% of the samples.
Immunohistology for ADOR protein expression
Cell-specific expression of ADOR protein was investi-
gated using two-color immunofluorescence. Primary
cell-specific monoclonal antibodies (mAbs) were used in
combination with goat polyclonal antibody specific for
ADORA2B (1:50; Abcam, Cambridge, UK) as previously
described [15]. For the detection of ADORA2A or
ADORA3, dual labeling with mAbs was utilized, based
on the following outline. However, certain combinations
of cell- and ADORA-specific mAbs required that the
AlexaFluor-conjugated, detection antibodies were
reversed. Briefly, tissue sections were first incubated
overnight at 4°C with mAbs specific for human
ADORA2A (1:100; Lifespan Biosciences, Seattle,
Washington, USA) or ADORA3 (1:100; Abnova, Taipei,
Taiwan), diluted in RPMI-1640 (GibcoBRL, Grand
Island, New York, USA)/10% FCS. Sections were washed
and bound mAb was detected by incubation with Alexa-
Fluor568-conjugated goat anti-mouse IgG (Invitrogen)
for 1.5 hours diluted in RPMI/10% FCS. Sections were
then sequentially washed, incubated with 1:1 PBS/10%
FCS: normal mouse serum (DAKO, Glostrup, Denmark)
for 30 minutes, washed, then incubated with an excess
of goat anti-mouse IgG(H+L) Fab fragments (Jackson
Immuno Research, Baltimore, Philadelphia, USA) for
one hour before a final wash. Primary cell-specific mAbs
were applied for 1.5 hours, and the sections washed
again before bound primary antibody was detected with
AlexaFluor488-conjugated goat anti-mouse IgG (Invitro-
gen) for 1.5 hours diluted in RPMI/10% FCS containing
1.25 mg/ml Hoechst 33342 nuclear stain (Molecular
Probes® Invitrogen, Eugene, Oregon, USA).
Statistical analysis
The test for Hardy-Weinberg equilibrium (HWE) was
performed using the internet-based program SHESIS
[16]. Assessment of linkage disequilibrium between the
two 5’UTR SNPs rs1544223 and rs1544224 was per-
formed using Haploview 4.2 and HapMap Data Rel 28
Phase II + III (assembly dbSNP b126).
Data were analyzed using Graph-pad Prism 4. All data
are presented as mean ± standard deviation (SD) unless
otherwise stated. The statistical significance of the dif-
ferences between the groups was determined by the
Mann-Whitney U test and correlation was tested using
the Spearman’s test.
Results
Demographics for the two patient cohorts are shown in
Table 1.
Expression of ADORA in synovial tissue
All five ADOR genes were expressed in all 20 synovial
tissues. ADORA3variant (A3V) and ADORA3 were the
dominant ADOR subtypes present. This was followed by
ADORA2B and ADORA1. ADORA2A was the least
expressed (Figure 1). There was a significant correlation
between ADORA2A and ADORA2B expression and
between ADORA3 and ADORA3V expression (Table 2).
Expression of ADORA2A and ADORA2B was signifi-
cantly higher in those patients receiving MTX (n = 11)
compared to those not receiving MTX (n = 9). However,
MTX had no apparent influence on expression of the
other ADOR genes (Figure 2). There was no relationship
between MTX dose and the amount of ADOR gene
expression. Only three patients were receiving anti-TNF
therapy without concomitant MTX. There was no sig-
nificant difference in the expression of any ADOR genes
between these three patients and the remaining patients
(P > 0.05; data not shown). Similarly there was no sig-
nificant difference in ADOR gene expression between
those patients receiving prednisone (n = 6) and those
not (n = 14) (P > 0.05; data not shown). There was no
significant correlation between expression of any of the
ADOR genes and ESR or serum CRP levels (data not
shown).
Cells expressing ADOR genes in RA synovial tissue
Consistent with the gene expression there was wide-
spread expression of ADORA3 protein within rheuma-
toid synovium, co-localized to fibroblasts (Figure 3).
Some, but not all infiltrating T cells stained weakly for
ADORA3 protein, as did interdigitating cells in the T
cell areas of synovial lymphoid follicles. In contrast
ADORA2B protein was most obvious in vascular
endothelial cells (ECs) that also expressed Factor VIII
(Figure 3). The ADORA2B-positive ECs had a cuboidal
morphology, consistent with activated endothelium.
However ADORA2B protein was also expressed by vas-
cular ECs with a flattened morphology in osteoarthritis
synovium (data not shown). ADOR2B protein was also
expressed by fibroblasts and by some aggregated T cells
in rheumatoid synovia but in amounts considerably less
than was observed in ECs. Expression of ADORA2A pro-
tein was rare and was generally restricted to large iso-
lated cells with a dendritic appearance. These latter cells
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have not been further identified. However ADOR2A pro-
tein was also observed in a solitary germinal center-
positive lymphoid follicle, consistent with follicular den-
dritic cell expression.
Sequence variants in ADORA3
A total of 15 SNPs were detected by sequencing ADORA3
across 15 patients with low disease activity (DAS28 ≤ 3.2)
and 15 patients with high disease activity (DAS28 > 3.2)
[See Additional file 2, Figure S1]. Of these polymorphisms,
two were located in the promoter, four in the 5’UTR, four
in the ORF, and five in the 3’UTR. All SNPs identified
have been previously reported in one or more populations.
Of the SNPs within the ORF, two were synonymous
(rs2789537 and rs2229155) and two were non-synon-
ymous (rs35511654 and rs2800889). Although none of the
variants were found exclusively in groups with high or low
disease activity, the minor allele frequencies (MAF) of the
5’UTR SNPs rs1544223 and rs1544224 were greater in the
high disease activity group (MAFhigh disease activity = 0.37
versus MAFlow disease activity = 0.13, P = 0.037). As a conse-
quence, SNP rs1544224 was genotyped in the complete
RA cohort using allele-specific PCR. The second SNP
rs1544223 was not genotyped as it was found to be in
complete linkage disequilibrium (LD) with rs1544224 in
the subset of patients sequenced and almost complete LD
(r2 = 0.974) in analysis of Utah residents with Northern
and Western European ancestry (CEU) and Tuscan in
Italy (TSI) from the HapMap Project.
Association between ADORA3 rs1544224 SNP and disease
activity, and MTX toxicity
Genotyping for rs1544224 was successful in 96.2% of
patients (225/234) and no deviation from HWE was
observed (P = 0.43). There was no association between
ADORA3 rs1544224 and any of the disease activity
Table 1 Demographic details of the two different patient cohorts used for genotyping and gene expression studies.
225 patients for ADORA polymorphisms 20 patients for synovial gene expression
Age (years) 59.5 (18 to 84) 66.4 (48 to 80)
% Female 72% 90%
Disease duration (years) 10.4 (0.17 to 57) 21.1 (3.7 to 47)
Nodules 56 (24.9%) 12 (60%)
Erosions 139 (61.8%) 19 (95%)
RF +positive 178 (79.1%) 17 (85%)
CCP positive 165/214 (77.1%) 11/15 (73.3%)
Receiving MTX 225 (100%) 11 (55%)
MTX dose (mean) (mg/wk) 15.8 (5 to 25) 16.4 (7.5 to 20)
ESR 16.6 (2 to 96) 41.4 (14 to 74) (n = 10)
CRP 10.9 (0 to 150) 18.9 (3 to 79) (n = 17)
Anti-TNF therapy 0 3 (15%)
Prednisone 71 (31.6%) 6 (30%)
ADOR, adenosine receptor; CCP, cyclic citrullinated peptide; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; MTX, methotrexate; TNF, tumor necrosis
factor; RF, rheumatoid factor.
Figure 1 Quantitative gene expression of ADOR in rheumatoid synovium. ADOR, adenosine receptor.
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variables (Table 3). There was no significant association
between ADORA3 rs1544224 genotype and low or high
disease activity groups (P = 0.76). Patients homozygous
for the minor allele were more likely to have ‘hair loss’
(P = 0.02) and ‘forgetfulness’ (P = 0.02), but there was
no other difference in adverse effects between the geno-
types [See Additional file 3, Table S2].
Discussion
MTX is an effective drug in the management of RA. Its
ability to suppress inflammation results, at least in part,
from its ability to increase extracellular concentrations
of adenosine which stimulates adenosine A2A and A3
receptors [4]. The primary site of inflammation in RA is
the synovium. Suppression of the inflammatory process
that drives this inflammation in the synovium and for-
mation of the tissue destructive pannus is critical to the
control of inflammatory joint symptoms and prevention
of joint erosion in RA.
Most attention with respect to the anti-inflammatory
mechanism of action of MTX has focused on the folate
pathway with less attention on the adenosine pathway.
ADORA3 has been reported to be expressed in PBMCs
[6,17] and ADORA1 and A2 in synovial fluid cells from
patients with RA [18] and isolated synoviocytes [19].
Both the adenosine A2A and A3 receptors, but not
ADORA1 or ADORA2B, have been reported to be up-
regulated in lymphocyte and neutrophil membranes
from patients with RA as compared to healthy controls
[20]. However, there have been no previous studies
examining expression of the adenosine receptors within
synovial tissue from patients with RA. Herein we have
demonstrated that the genes for all four adenosine
receptors are expressed at varying levels in rheumatoid
synovium.
ADORA3 was expressed significantly more than the
other ADOR genes. This may be the result of the inflam-
matory process occurring within the synovium, with pre-
vious reports suggesting that expression of ADORA3 is
up-regulated by TNF-a via activation of NFB [17,20].
ADORA2A, through which MTX is also thought to exert
its anti-inflammatory effects, was expressed in the lowest
amounts of all the ADOR subtypes [7].
Table 2 Correlation between expression of different
ADORA genes in rheumatoid synovium.
ADORA2A ADORA2B ADORA3 ADORA3V Combined
ADORA3
ADORA1
Spearman r 0.45 0.09 0.21 0.25 0.26
P 0.04 0.71 0.37 0.29 0.27
ADORA2A
Spearman r 0.66 0.21 0.29 0.30
P 0.002 0.37 0.20 0.19
ADORA2B
Spearman r 0.31 0.24 0.26




Figure 2 Influence of MTX on the expression of ADOR genes in RA synovial tissue. ADOR, adenosine receptor; MTX, methotrexate; RA,
rheumatoid arthritis.
Stamp et al. Arthritis Research & Therapy 2012, 14:R138
http://arthritis-research.com/content/14/3/R138
Page 5 of 9
Several possibilities could explain the difference in
expression of the various adenosine receptor subtypes.
These include the cellular constituents of the tissue
examined. Consistent with this possibility, ADORA3
protein expression was more widespread in synovial tis-
sue. In contrast ADORA2B protein was prominent in
vascular ECs but also present in fibroblasts and some T
cells, albeit in much reduced amounts; ADORA2A pro-
tein was restricted to cells with a dendritic appearance.
Overall, the patterns of ADOR protein distribution were
consistent with the hierarchical order we observed for
expression of the corresponding ADOR genes. For all
ADOR subtypes, we did not observe significant protein
associated with the infiltrating inflammatory cells. We
are not able to exclude that these patterns of protein
expression and the differences in gene expression could
also be affected by the inflammatory cytokine milieu
within the synovium. However, we further considered
the effect of anti-rheumatic therapy and the possible
influence on ADORA expression.
Both MTX and anti-TNF therapy have been reported
to have effects on adenosine receptor expression and
affinity. MTX therapy results in up-regulation of the
ADORA2A and ADORA3, but not ADORA1 or
ADORA2B expression in lymphocyte and neutrophil
membranes from RA patients as compared to healthy
controls [20]. The up-regulation of ADORA3 expres-
sion on PBMCs has been observed after only ten
Figure 3 ADORA protein expression. Two-color immunofluorescence detecting ADORA2A (A; red), ADORA2B (B; green) and ADORA3 (C; red)
protein expression in combination with cell specific markers (indicated) CD 31(B; red) and CD3 (C; green) in rheumatoid synovia. Co-localized
staining appears yellow. ADOR, adenosine receptor.
Table 3 Univariate associations between ADORA3 rs1544224 and disease activity.
Variable Genotypea Allelic P value
11 12 22
SJC (28) 2.9 ± 3.4 2.7 ± 3.9 3.0 ± 3.0 0.89
123 (54.7%) 84 (37.6%) 18 (8.2%)
TJC (28) 2.5 ± 3.5 2.4 ± 3.9 1.7 ± 2.3 0.65
123 (54.7%) 84 (37.6%) 18 (8.2%)
DAS28 2.9 ± 1.2 2.9 ± 1.3 2.9 ± 1.1 0.99
123 (54.7%) 84 (37.6%) 18 (8.2%)
CRP 1.2 ± 2.1 1.1 ± 1.4 1.1 ± 0.9 0.98
105 (46.7%) 66 (29.3%) 16 (7.1%)
Physicians global 23.5 ± 19.5 22.0 ± 19.8 15.5 ± 12.7 0.26
123 (54.7%) 84 (37.6%) 18 (8.2%)
Physicians response to MTX 22.9 ± 18.9 22.2 ± 20.7 14.5 ± 13.6 0.23
118 (52.4%) 71 (9.3%) 18 (8.2%)
Pain VAS 23.6 ± 22.8 22.8 ± 23.9 20.1 ± 22.9 0.83
123 (54.7%) 84 (37.6%) 18 (8.2%)
Patient global 26.4 ± 21.9 27.6 ± 24.6 23.7 ± 17.1 0.79
123 (54.7%) 84 (37.6%) 18 (8.2%)
mHAQ 0.42 ± 0.49 0.42 ± 0.45 0.37 ± 0.47 0.89
123 (54.7%) 84 (37.6%) 18 (8.2%)
a1 = major allele, 2 = minor allele of rs1544224. Top row mean ± SD, bottom row number of patients. CRP, C-reactive protein; DAS28, disease activity score in 28
joints; HAQ, Health Assessment Questionnaire; MTX, methotrexate; SD, standard deviation; SJC, swollen joint count; TJC, tender joint count; VAS, visual analog
scale.
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weeks of MTX therapy [5]. In addition, the affinity of
the ADORA2A and ADORA3 was lower in patients
receiving MTX compared to healthy controls [20]. In
comparison, in RA patients receiving anti-TNF therapy
the expression and affinity of ADORA2A and ADORA3
was similar to that observed in healthy controls [20].
This is consistent with an effect of TNF or the indirect
effect of inflammation in general. In our cohort,
expression of ADORA2A and ADORA2B but not
ADORA3, was increased in those patients receiving
MTX compared to those not receiving MTX. While
we observed no effect of anti-TNF therapy, the number
of patients was small. The presence of the adenosine
receptors in the synovial membrane provides evidence
that MTX has the potential to exert important anti-
inflammatory effects at the primary site of the inflam-
matory process in RA.
It is important to note that the specimens used in our
study were from RA patients with late stage disease and
these patients differed from the cohort used for the gen-
otyping studies. There remains a possibility that changes
in ADOR subtype expression related to MTX therapy
could be different at earlier stages of disease. However,
given that expression of ADORA2A, ADORA2B and
ADORA3 is regulated by inflammatory cytokines such as
TNF-a [6-8] it would be reasonable to assume there
may be similar findings. This will need to be confirmed
in studies of patients with early RA.
Signalling through ADOR depends on a variety of fac-
tors including receptor expression, receptor sensitivity
and extra-cellular concentration of ligand. Our data
show greatest gene expression of ADOR3 and the
ADOR3VAR in rheumatoid synovia and that expression
of a designated ADOR subtype is not necessarily exclu-
sive to a particular cell type. Furthermore, there are
known variations in the kinetic properties of the differ-
ent ADOR subtypes, with ADORA1, ADORA2A and
ADORA3 several orders of magnitude more sensitive to
adenosine than ADORA2B [21]. It remains to be deter-
mined whether variation in expression compensates for
the different kinetics attributed to the different ADOR
subtypes and what consequences this has for individual
synovial cell types.
The importance of ADORA3 in the anti-inflammatory
process has also been highlighted by the finding in acti-
vated PBMCs that addition of an adenosine agonist (IB-
MECA, CF101) resulted in reduced ADORA3 expression
and down-regulation of TNF-a, thus breaking the auto-
crine loop and inhibiting the inflammatory process [17].
The clinical efficacy of an oral adenosine A3 receptor
agonist, CF101, in patients with RA has been examined
in a small 12-week study. The level of expression of
ADORA3 in PBMCs at baseline correlated with ACR50
and ACR70 responses (P = 0.036) [22]. We have now
demonstrated high levels of ADORA3 expression in the
joint tissues targeted by the inflammation. These data
provide an encouraging line of evidence for further
investigation of adenosine A3 agonists as therapeutic
agents in RA, particularly in patients with high levels of
ADORA3 expression.
MTX has also been suggested to have a beneficial
effect on cardiovascular mortality in RA, an effect that is
not observed with other disease modifying anti-rheu-
matic drugs (DMARDs) [23,24]. This effect appears to
be mediated through ADORA2A activation mediating
reverse cholesterol transport and limiting foam cell for-
mation [25]. One of the key challenges in the manage-
ment of RA is rapid and effective disease control
without provoking adverse effects. Currently there is no
reliable means to predict which patients will respond to
MTX, nor who will experience adverse effects. In this
regard efforts have focused on the ability of polymorph-
isms of genes involved in the folate pathway to predict
efficacy and toxicity of MTX. To date no SNP or combi-
nation of SNPs within the folate pathway has been iden-
tified that will reliably predict response or adverse
effects associated with MTX.
Polymorphisms of adenosine monophosphate deami-
nase 1 (AMPD1), aminoimidazole carboxamide ribonu-
cleotide transformylase (ATIC), and inosine
triphosphate pyrophosphatase (ITPA), which are
involved in the adenosine pathway, have been asso-
ciated with good clinical response to MTX in patients
with RA in some but not all studies [26,27]. Genetic
variations in the ADOR genes have received less atten-
tion but have been reported to be associated with good
clinical response to MTX [26] or have no effect [27].
Polymorphisms within the ADORA2A gene have been
associated with adverse gastrointestinal events (nausea,
vomiting or diarrhea) associated with MTX in patients
with RA [28]. Herein we have investigated polymorph-
isms within the ADORA3 gene. We have shown that
the SNP rs1544224 is not associated with disease activ-
ity in patients with RA receiving MTX. Whether this
SNP can predict MTX efficacy will need to be formally
examined in prospective clinical studies. The cross-sec-
tional design of this study resulted in the cohort of
patients being enriched for patients who tolerated
MTX. Patients with more severe adverse effects such
as hepatotoxicity or myelotoxicity would have discon-
tinued MTX and not entered this study. Nevertheless,
there are a number of other adverse effects associated
with MTX for which patients elect not to discontinue
therapy because the benefits of therapy outweigh the
adverse effects. We have shown a weak association
between the ADORA3 rs1544224 SNP and forgetful-
ness and hair loss in our cohort. Confirmation of this
will be required in other cohorts.
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Conclusions
In conclusion, we have shown that genes for adenosine
receptors are expressed in RA synovium. There is differ-
ential expression of receptors such that ADORA3 is
expressed at significantly higher levels. This evidence
demonstrates the potential for MTX to exert its anti-
inflammatory effects at the primary site of pathology
within the joints of patients with RA.
Additional material
Additional file 1: Supplementary Table S1. Primers used for
amplification, sequencing, and genotyping of ADORA3.
Additional file 2: Supplementary Figure 1. Genomic organization of
ADORA3. The ADORA3 gene is localized to chromosome 1p21-p13 and
comprises two exons separated by a single large intron (not shown to
scale). Untranslated regions (UTRs) and the open reading frame (ORF) are
represented by light and dark grey rectangles, respectively. Location of
single nucleotide polymorphisms (SNPs) found by sequencing 15 RA
patients with low disease activity (DAS28 ≤ 3.2) and 15 RA patients with
high disease activity (DAS28 > 3.2) are indicated by vertical arrows.
Additional file 3: Supplementary Table S2. Univariate associations
between ADORA3 rs1544224 and MTX adverse effects. Top row number
of patients and bottom row percentage.
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